PrEP demo project finds the people at highest HIV risk generally take PrEP most consistently

nam, 27 July 2015

An open-label demonstration project of Truvada pre-exposure prophylaxis (PrEP) in the United States has found generally high retention and adherence rates, with the highest adherence among those at the highest risk of HIV.

Read more here

Share Button